SNYSanofiRunning, no new patients
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 118 (final count)
- Started
- Apr 5, 2023
- Main results expected
- Dec 22, 2025
- Fully finished
- May 12, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall response rate (ORR) - Cohorts 1 to 3
Measured over: 6 months after the Last Participant In (LPI) i.e., approximately 16 months
Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5
Measured over: Cycle 1 (28 days)
Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5
Measured over: Cycle 1 (28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05704049 · record last updated 2025-12-29 · checked 2026-11-09 15:47 UTC